000274190 001__ 274190
000274190 005__ 20251118115451.0
000274190 0247_ $$2doi$$a10.1016/j.jhep.2023.02.033
000274190 0247_ $$2pmid$$apmid:36893854
000274190 0247_ $$2ISSN$$a0168-8278
000274190 0247_ $$2ISSN$$a1600-0641
000274190 0247_ $$2altmetric$$aaltmetric:143649823
000274190 037__ $$aDKFZ-2023-00485
000274190 041__ $$aEnglish
000274190 082__ $$a610
000274190 1001_ $$0P:(DE-He78)241fe8af1e038118cd817048a65f803e$$aYahoo, Neda$$b0$$eFirst author$$udkfz
000274190 245__ $$aRole of immune responses for development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
000274190 260__ $$a[Erscheinungsort nicht ermittelbar]$$bWiley-Blackwell$$c2023
000274190 3367_ $$2DRIVER$$aarticle
000274190 3367_ $$2DataCite$$aOutput Types/Journal article
000274190 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763463279_1939189$$xReview Article
000274190 3367_ $$2BibTeX$$aARTICLE
000274190 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274190 3367_ $$00$$2EndNote$$aJournal Article
000274190 500__ $$a#EA:F180#LA:F180# / 2023 Aug;79(2):538-551 / #DKFZ-MOST-Ca197#
000274190 520__ $$aThe liver is the central metabolic organ of the body regulating energy and lipid metabolism and at the same time has potent immunological functions. Overwhelming the metabolic capacity of the liver by obesity and sedentary lifestyle leads to hepatic lipid accumulation, chronic necro-inflammation, enhanced mitochondrial/ER-stress and development of non-alcoholic fatty liver disease (NAFLD), with its pathologic form nonalcoholic steatohepatitis (NASH). Based on knowledge on pathophysiological mechanisms, specifically targeting metabolic diseases to prevent or slow down progression of NAFLD to liver cancer will become possible. Genetic/environmental factors contribute to development of NASH and liver cancer progression. The complex pathophysiology of NAFLD-NASH is reflected by environmental factors, particularly the gut microbiome and its metabolic products. NAFLD-associated HCC occurs in most of the cases in the context of a chronically inflamed liver and cirrhosis. Recognition of environmental alarmins or metabolites derived from the gut microbiota and the metabolically injured liver create a strong inflammatory milieu supported by innate and adaptive immunity. Several recent studies indicate that the chronic hepatic microenvironment of steatosis induces auto-aggressive CD8+CXCR6+PD1+ T cells secreting TNF and upregulating FasL to eliminate parenchymal and non-parenchymal cells in an antigen independent manner. This promotes chronic liver damage and a pro-tumorigenic environment. CD8+CXCR6+PD1+ T cells possess an exhausted, hyperactivated, resident phenotype and trigger NASH to HCC transition, and might be responsible for a less efficient treatment response to immune-check-point inhibitors - in particular atezolizumab/bevacizumab. Here, we provide an overview of NASH-related inflammation/pathogenesis focusing on new discoveries on the role of T cells in NASH-immunopathology and therapy response. This review discusses preventive measures to halt disease progression to liver cancer and therapeutic strategies to manage NASH-HCC patients.
000274190 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000274190 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000274190 650_7 $$2Other$$aFatty liver disease
000274190 650_7 $$2Other$$aT cell auto-aggression
000274190 650_7 $$2Other$$ahepatocellular carcinoma
000274190 650_7 $$2Other$$aimmune cell activation
000274190 650_7 $$2Other$$aimmune-mediated liver damage
000274190 650_7 $$2Other$$aimmunotherapy of liver cancer
000274190 7001_ $$aDudek, Michael$$b1
000274190 7001_ $$aKnolle, Percy$$b2
000274190 7001_ $$0P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aHeikenwälder, Mathias$$b3$$eLast author$$udkfz
000274190 773__ $$0PERI:(DE-600)2027112-8$$a10.1016/j.jhep.2023.02.033$$gp. S0168827823001654$$n2$$p538-551$$tJournal of hepatology$$v79$$x0168-8278$$y2023
000274190 909CO $$ooai:inrepo02.dkfz.de:274190$$pVDB
000274190 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)241fe8af1e038118cd817048a65f803e$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000274190 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000274190 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000274190 9141_ $$y2023
000274190 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-09
000274190 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-09
000274190 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-09
000274190 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000274190 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000274190 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000274190 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000274190 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-24
000274190 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000274190 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-24
000274190 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000274190 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ HEPATOL : 2022$$d2023-10-24
000274190 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
000274190 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
000274190 915__ $$0StatID:(DE-HGF)9925$$2StatID$$aIF >= 25$$bJ HEPATOL : 2022$$d2023-10-24
000274190 9202_ $$0I:(DE-He78)F180-20160331$$kF180$$lChronische Entzündung und Krebs$$x0
000274190 9201_ $$0I:(DE-He78)F180-20160331$$kF180$$lChronische Entzündung und Krebs$$x0
000274190 9200_ $$0I:(DE-He78)F180-20160331$$kF180$$lChronische Entzündung und Krebs$$x0
000274190 980__ $$ajournal
000274190 980__ $$aVDB
000274190 980__ $$aI:(DE-He78)F180-20160331
000274190 980__ $$aUNRESTRICTED